Back to Trial

Oracle Runs

Oracle findings and outcome history for Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously (NCT04594850).

Runs
6
Findings
6
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial completed Jan 2026 per ClinicalTrials.gov, but no results posted and no public readout found in searches across web, sponsor site, news. No sources frame readout as positive or negative; evidence incomplete.

Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
Web Searchclinicaltrials.govApr 5, 2026, 5:51 PM
ClinicalTrials.gov NCT04594850 Study Record
Status: Completed. Primary/Study completion: 2026-01-07. No results section or efficacy data posted.
Web Searchpharmicell.comSep 23, 2021, 12:00 AM
Pharmicell Press Release on Cellgram-ED Phase 1
Phase 1 results published: safe, IIEF total score up to 38% vs baseline in small open-label trial. No Phase 2 data.
NO_DECISIONDismissed80% confidenceGrok 4.20 (xAI)

Will the results be positive?

NCT04594850 completed primary endpoint Jan 2026 with last update Feb 2026; no public results, IIEF changes, or sponsor statements posted. Prior phase 1 (different NCT) showed IIEF improvement and 'potential efficacy' but not this exact trial. No positive/negative framing located for this Phase 2.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM
Web Searchclinicaltrials.govFeb 6, 2026, 12:00 AM
Study Details | NCT04594850 | ClinicalTrials.gov
Completed. Primary Completion (Actual) 2026-01-07. Last Update Posted: 2026-02-06. No results posted; primary endpoint is change in IIEF EF score at 6 months (ANCOVA).
Web Searchadisinsight.springer.comJan 7, 2026, 12:00 AM
Autologous mesenchymal stem cell therapy - Pharmicell - AdisInsight
Pharmicell completes a phase-II Cellgram-ED clinical trial in Erectile dysfunction... (NCT04594850). No efficacy results or interpretation provided.
Web Searchisct-cytotherapy.org
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial
Phase 1 (not this trial): mean IIEF score increased significantly at 1 month (24.9 vs 18.1, p=0.0222). Confirmed safety and potential efficacy. Phase 1 only.
NO_DECISIONDismissed80% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Found Apr 4, 2026, 8:52 PMReviewed Apr 4, 2026, 10:32 PM
ClinicalTrialsclinicaltrials.govFeb 9, 2026, 12:00 AM
Study Details | NCT04594850 | ClinicalTrials.gov
ClinicalTrials.gov lists completed; primary completion 2026-01-07; hasResults=false on the latest posted update.
NO_DECISIONDismissed88% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No public Phase 2 efficacy readout framing this exact trial as positive or negative was found. Sponsor materials still described Cellgram-ED Phase 2 as ongoing/planned, while the registry mirror shows completion dates only, not interpreted results. Evidence is incomplete and not readout-specific.

Found Apr 3, 2026, 5:20 PMReviewed Apr 3, 2026, 5:20 PM
Sponsorpharmicell.comMar 18, 2025, 12:00 AM
Pharmicell 2025 business report
Company report lists Cellgram-ED for erectile dysfunction as Phase 2 approved; first patient Oct 2020, last patient enrolled Dec 2024, and future plan says the commercial Phase 2 trial is in progress. No Phase 2 outcome interpretation is given.
ClinicalTrialsichgcp.netFeb 6, 2026, 12:00 AM
Cellgram-ED in Erectile Dysfunction - Clinical Trials Registry - ICH GCP
Registry mirror for NCT04594850 shows status Completed, Phase 2, actual primary completion and study completion on 2026-01-07, last update posted 2026-02-09. It provides design/timing details but no public positive or negative results framing.
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear positive or negative public readout was found for NCT04594850. The cited sources show the Phase 2 study completed on January 7, 2026, but sponsor materials only described it as enrollment complete/under follow-up, and a March 2026 safety follow-up study was launched. That is insufficient for a trial-specific efficacy verdict.

Found Apr 2, 2026, 5:15 PMReviewed Apr 3, 2026, 4:48 PM
ClinicalTrialsichgcp.netFeb 6, 2026, 12:00 AM
Cellgram-ED in Erectile Dysfunction - Clinical Trials Registry
Registry entry for NCT04594850 shows Status: Completed; Primary Completion (Actual): January 7, 2026; Study Completion (Actual): January 7, 2026. It provides design details but no positive/negative efficacy interpretation.
Sponsorfile.alphasquare.co.krJul 11, 2025, 12:00 AM
PHARMICELL Investor Relations deck
Sponsor IR slide states Cellgram-ED Phase 2 had patient recruitment completed and was under follow-up observation; it does not report or frame trial efficacy results as positive or negative.
Web Searchurotoday.comMar 9, 2026, 12:00 AM
A Safety Follow-up Study of a Phase 2 Clinical Trial Evaluating Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction
March 2026 listing describes a new observational safety follow-up study for participants from the parent Cellgram-ED trial, indicating post-trial follow-up rather than a public efficacy readout.
NO_DECISIONDismissed89% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear public efficacy readout was found for NCT04594850. Sponsor materials show the Phase 2 trial was still ongoing as of March 18, 2025, and later reporting says it completed and entered follow-up observation, but neither source provides a trial-specific positive or negative interpretation.

Found Mar 31, 2026, 9:48 PMReviewed Apr 1, 2026, 6:34 AM
Sponsorpharmicell.comMar 18, 2025, 12:00 AM
Pharmicell business report (2025-03-18)
Sponsor pipeline section for Cellgram-ED says first patient enrolled Oct 2020, last patient enrolled Dec 2024, and Phase 2 was still in progress; no efficacy conclusion is stated.
Web Searchbiz.chosun.comNov 10, 2025, 12:00 AM
Pharmicell CEO Kim Hyun-su combines stem cells and AI to pursue reverse aging and DNA memory
Article says Cellgram-ED Phase 2 had completed and was under follow-up observation. It does not report trial-specific efficacy results or frame the readout as positive or negative.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.